会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Charged therapeutic agents encapsulated in lipid particles containing four lipid components
    • 包含在含有四种脂质组分的脂质颗粒中的带电治疗剂
    • US06287591B1
    • 2001-09-11
    • US09078954
    • 1998-05-14
    • Sean C. SempleSandra K. KlimukTroy HarasymMichael J. HopeSteven M. AnsellPieter CullisPeter ScherrerDan Debeyer
    • Sean C. SempleSandra K. KlimukTroy HarasymMichael J. HopeSteven M. AnsellPieter CullisPeter ScherrerDan Debeyer
    • A61K9127
    • A61K9/1277A61K9/1272Y10T428/2984
    • Lipid-therapeutic agent particles are prepared containing a charged therapeutic agent encapsulated in lipid portion containing at least two lipid components including a protonatable or deprotonatable lipid such as an amino lipid and a lipid that prevents particle aggregation during lipid-therapeutic agent particle formation such as a PEG-modified or polyamide oligomer-modified lipid. Other lipid components may also be present and these include a neutral lipid such as DSPC, POPC, DOPE or SM, and a sterol such as Chol. The therapeutic agent is encapsulated by combining a mixture of the lipids with a buffered aqueous solution of a charged therapeutic agent to form an intermediate mixture containing lipid-encapsulated therapeutic agent particles, and changing the pH of the intermediate mixture to neutralize at least some surface charges on the particles. The method permits high ratios of therapeutic agent to lipid and encapsulation efficiencies in excess of 50%. The method is particularly useful for preparing lipid-encapsulated nucleic acids such as an antisense polyanionic nucleic acid having exclusively phosphodiester linkages. The encapsulated nucleic acid can be contacted with a cell to introduce the nucleic acid into the cell such as for treatment or prevention of a disease characterized by aberrant expression of a gene. A pharmaceutical composition may be prepared containing the lipid-encapsulated therapeutic agent particles and a carrier.
    • 制备包含含有至少两种脂质组分的脂质部分的带电治疗剂的脂质治疗剂颗粒,所述脂质组分包括可质子化或可去质子化的脂质如氨基脂质和防止脂质治疗剂颗粒形成期间的颗粒聚集的脂质,例如 PEG修饰或聚酰胺低聚物修饰的脂质。 其他脂质组分也可以存在,它们包括中性脂质如DSPC,POPC,DOPE或SM,以及甾醇如Chol。 通过将所述脂质的混合物与带电治疗剂的缓冲水溶液组合以形成含有脂质包封的治疗剂颗粒的中间体混合物并改变中间体混合物的pH以中和至少一些表面电荷来封装治疗剂 在颗粒上。 该方法允许高比例的治疗剂与脂质和包封效率超过50%。 该方法特别可用于制备脂质包封的核酸,例如仅具有磷酸二酯键的反义聚阴离子核酸。 封装的核酸可以与细胞接触以将核酸引入细胞,例如用于治疗或预防以基因异常表达为特征的疾病。 可以制备含有脂质包封的治疗剂颗粒和载体的药物组合物。